Regulating Surrogate Advertising: Celebrity Endorsements and Consumer Protection

GS-III: Economy | Consumer Protection | Public Health | Regulatory Governance | Tobacco Control

Context

• Maharashtra FDA action: Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has targeted celebrities endorsing products suspected of being surrogate advertisements for tobacco.
• Vimal Elaichi: The FDA argues that Vimal Elaichi, endorsed by Shah Rukh Khan, Ajay Devgn and Tiger Shroff, does not have an independent market identity from tobacco products.
• Surrogate advertising: According to the FDA, promoting such a product can effectively amount to indirect promotion of tobacco products.
• Public health concern: India bears a very high burden of oral cancer, making tobacco-related advertising a serious public-health issue.
• Core issue: The challenge is to regulate misleading or surrogate advertising while ensuring that enforcement remains fair, evidence-based and legally sustainable.

Legal Framework

• COTPA: The Cigarettes and Other Tobacco Products Act (COTPA) and its Rules regulate tobacco advertising and related promotional practices.
• Delhi High Court: In DGHS v. Som Pan Product Pvt. Ltd. (2024), the Court held that the State has the responsibility to prove a case of surrogate advertising.
• Brand registration: Mere registration of a brand cannot by itself establish surrogate advertising.
• Legal product: The mere existence of a technically legal product does not automatically make its advertisement permissible.
• Consumer Protection Act, 2019: It creates liability for endorsers and provides for financial penalties in cases involving misleading advertisements.
• Food Safety and Standards Act, 2006: The FDA can also examine advertisements involving food-related products and claims.

Why Celebrity Endorsements Matter

• Brand recall: Celebrities possess significant persuasive power and public visibility.
• Asymmetry of risk: The celebrity may face little or none of the economic or health consequences suffered by consumers after purchasing certain products.
• Consumer influence: Uncritical celebrity endorsement can influence consumer behaviour, particularly among young and impressionable audiences.
• Endorser responsibility: The Consumer Protection Act has reduced the scope for celebrities to simply claim ignorance of the manufacturer’s intentions.
• FDA approach: Asking celebrity endorsers to explain their decision-making process is a logical extension of this principle.

Beyond Tobacco

• Unsubstantiated claims: Similar concerns arise with products claiming to “boost immunity” without adequate evidence.
• Educational products: Misleading claims regarding outcomes, placements or guaranteed success can exploit consumers.
• Financial products: Advertisements may make unrealistic or unsubstantiated claims regarding returns and financial benefits.
• Common concern: In all such cases, celebrity influence can amplify the impact of misleading claims.

Regulatory Challenges

• Fragmented framework: India’s advertising regulation is spread across a range of Acts and Rules.
• Legal complexity: Problematic advertisements can invoke different legal and administrative provisions.
• Judicial intervention: Regulatory actions may ultimately require judicial scrutiny.
• Proof requirement: Regulators must establish the connection between a promoted product and the prohibited product rather than relying merely on suspicion.
• Risk of overreach: Excessive or poorly substantiated action can undermine regulatory credibility and due process.

Way Forward

• Evidence-based enforcement: The FDA should conduct inquiries under COTPA and the Food Safety and Standards Act, 2006 that can withstand judicial scrutiny.
• Celebrity accountability: Endorsers should exercise reasonable due diligence before promoting products.
• Clear standards: Establish clearer criteria for identifying surrogate and misleading advertisements.
• Consumer protection: Strengthen mechanisms against unsubstantiated health, educational and financial claims.
• Regulatory coordination: Improve coordination among different agencies dealing with advertising and consumer protection.
• Balanced regulation: Penalties and bans should be imposed where justified, while ensuring that regulatory action does not become arbitrary or excessive.

Conclusion

Celebrity endorsements can significantly shape consumer behaviour, making them an important part of the regulatory landscape. The FDA’s action is therefore significant, particularly in the context of tobacco and public health. However, effective regulation requires a balance between consumer protection and procedural fairness. Regulatory action must be based on evidence, proportionality and clear legal standards; otherwise, an attempt to curb surrogate advertising could itself become an example of regulatory overreach.

UPSC Mains Practice Question

Q. “Celebrity endorsements can amplify both consumer choice and consumer harm.” Discuss the challenges of regulating surrogate and misleading advertisements in India with reference to tobacco products and the Consumer Protection Act, 2019.